Biocon Biologics has settled patent disputes with Bayer Inc and Regeneron Pharmaceuticals Inc, enabling the launch of Yesafili, an ophthalmology product for neovascular and age-related macular degeneration, in Canada by July 1, 2025.
Disclaimer : Mymoneytimes implements extreme caution and care in collecting data before publication. Mymoneytimes does not liable for the adequacy, accuracy or completeness of any given information. Hence we are not liable for any kind of direct or indirect loss caused by the use of such information.